{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:46Z","timestamp":1793225986740,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cllc.2024.07.017","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T16:26:20Z","timestamp":1722702380000},"page":"624-633.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-8316","authenticated-orcid":false,"given":"Felipe","family":"Soto-Lanza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumil","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie R.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Franco-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-0180","authenticated-orcid":false,"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cllc.2024.07.017_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.cllc.2024.07.017_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"10.1016\/j.cllc.2024.07.017_bib0003","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cllc.2024.07.017_bib0004","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III poseidon study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.cllc.2024.07.017_bib0005","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage iv or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.cllc.2024.07.017_bib0006","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cllc.2024.07.017_bib0007","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1\u2013positive advanced nsclc","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2024.07.017_bib0008","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.cllc.2024.07.017_bib0009","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2024.07.017_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cllc.2024.07.017_bib0011","article-title":"Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"J Io Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2024.07.017_bib0012","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/1759-7714.13187","article-title":"High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer","volume":"10","author":"Tone","year":"2019","journal-title":"Thoracic Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.07.017_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68372-w","article-title":"Association of lung function with overall mortality is independent of inflammatory, cardiac, and functional biomarkers in older adults: the ActiFE-study","volume":"10","author":"Weinmayr","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2024.07.017_bib0014","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2021.11.012","article-title":"Modifiable factors associated with health-related quality of life among lung cancer survivors following curative intent therapy","volume":"163","author":"Ha","year":"2022","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2024.07.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2024.07.017_bib0016","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clon.2023.07.003","article-title":"Pneumonitis after concurrent chemoradiation and immune checkpoint inhibition in patients with locally advanced non-small cell lung cancer","volume":"35","author":"Altan","year":"2023","journal-title":"Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2024.07.017_bib0017","doi-asserted-by":"crossref","first-page":"e1065","DOI":"10.1093\/oncolo\/oyad118","article-title":"Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced non-small cell lung cancer: a single center experience","volume":"28","author":"Altan","year":"2023","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.cllc.2024.07.017_bib0018","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society","volume":"8","author":"Hatabu","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"issue":"1","key":"10.1016\/j.cllc.2024.07.017_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2024.07.017_bib0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00520-006-0178-7","article-title":"The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer","volume":"15","author":"Gupta","year":"2007","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2024.07.017_bib0021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1590\/S1806-37132007000200010","article-title":"Influ\u00eancia do sistema de fornecimento de oxig\u00eanio na qualidade de vida de pacientes com hipoxemia cr\u00f4nica","volume":"33","author":"Tanni","year":"2007","journal-title":"Jornal Brasileiro de Pneumologia"},{"issue":"3","key":"10.1016\/j.cllc.2024.07.017_bib0022","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02107-2019","article-title":"Association of dyspnoea, mortality and resource use in hospitalised patients","volume":"58","author":"Stevens","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.cllc.2024.07.017_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-015-0003-5","article-title":"Low oxygen saturation and mortality in an adult cohort: the Troms\u00f8 study","volume":"15","author":"Vold","year":"2015","journal-title":"BMC Pulmonary Medicine"},{"issue":"11","key":"10.1016\/j.cllc.2024.07.017_bib0024","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.6004\/jnccn.2023.7059","article-title":"Association between pretreatment chest imaging and immune checkpoint inhibitor pneumonitis among patients with lung cancer","volume":"21","author":"Wong","year":"2023","journal-title":"J Nat Comprehens Cancer Netw"},{"issue":"1","key":"10.1016\/j.cllc.2024.07.017_bib0025","first-page":"e108","article-title":"Pre-existing interstitial lung abnormalities and immune checkpoint inhibitor-related pneumonitis in solid tumors: a retrospective analysis","volume":"29","author":"Horiuchi","year":"2024","journal-title":"Onc"},{"issue":"11","key":"10.1016\/j.cllc.2024.07.017_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22906","article-title":"Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor\u2013induced interstitial lung disease among patients with nonlung cancers","volume":"3","author":"Shimoji","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cllc.2024.07.017_bib0027","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2017.02.012","article-title":"FEV1 and FVC predict all-cause mortality independent of cardiac function\u2014results from the population-based gutenberg health study","volume":"234","author":"Magnussen","year":"2017","journal-title":"Int J Cardiol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:48:42Z","timestamp":1729871322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424001554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1525730424001554"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.07.017","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}